Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Add as a preferred source on Google
SAN DIEGO, May 07, 2018 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 7194327
Prior to the webcast at approximately 4:30 PM Eastern Time on May 10, Cytori will issue its first quarter earnings release which will review Cytori’s first quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]
